The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

banner

Acura Pharmaceuticals USPTO Issues Notice of Allowance for Novel Limitx(TM) Abuse Deterrent Technology

29-Jun-2015 | Source : AG-IP News | Visits : 4256
PALATINE, IL - Acura Pharmaceuticals Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, announced in a press release receipt from the United States Patent and Trademark Office ("USPTO") of a Notice of Allowance for a non-provisional patent application related to our abuse deterrent LIMITX™ Technology platform. A US patent relating to this Notice of Allowance will be granted by the USPTO after the Company pays the required fees.

Claims in the underlying patent application are the basis of our LIMITX Technology which is designed to address opioid abuse via the oral route of administration. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested.

When issued, this will be the first US patent directed at products developed with the LIMITX Technology.
 
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX™, AVERSION® and IMPEDE® Technologies. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.
 
share



Related Articles